Modulation of host lipid metabolism by hepatitis C virus: Role of new therapies
- PMID: 26478669
- PMCID: PMC4600579
- DOI: 10.3748/wjg.v21.i38.10776
Modulation of host lipid metabolism by hepatitis C virus: Role of new therapies
Abstract
It is well established that hepatitis C virus (HCV) infection and replication relies on host lipid metabolism. HCV proteins interact and associate with lipid droplets to facilitate virion assembly and production. Besides, circulating infective particles are associated with very low-density lipoprotein. On the other hand, higher serum lipid levels have been associated with sustained viral response to pegylated interferon and ribavirin therapy in chronic HCV infection, suggesting a relevant role in viral clearance for host proteins. Host and viral genetic factors play an essential role in chronic infection. Lipid metabolism is hijacked by viral infection and could determine the success of viral replication. Recently development of direct acting antiviral agents has shown a very high efficacy (> 90%) in sustained viral response rates even for cirrhotic patients and most of the viral genotypes. HCV RNA clearance induced by Sofosbuvir has been associated with an increased concentration and size of the low-density lipoprotein particles. In this review, host genetic factors, viral factors and the interaction between them will be depicted to clarify the major issues involved in viral infection and lipid metabolism.
Keywords: Direct acting antiviral agents; Genetic interaction; Hepatitis C virus; Lipid metabolism; Sofosbuvir.
Figures

Similar articles
-
Lipids: a key for hepatitis C virus entry and a potential target for antiviral strategies.Biochimie. 2013 Jan;95(1):96-102. doi: 10.1016/j.biochi.2012.07.016. Epub 2012 Aug 1. Biochimie. 2013. PMID: 22884392 Review.
-
Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9.EBioMedicine. 2017 Sep;23:68-78. doi: 10.1016/j.ebiom.2017.08.020. Epub 2017 Aug 24. EBioMedicine. 2017. PMID: 28864162 Free PMC article.
-
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.Gastroenterology. 2015 Jan;148(1):108-17. doi: 10.1053/j.gastro.2014.10.001. Epub 2014 Oct 7. Gastroenterology. 2015. PMID: 25304641 Clinical Trial.
-
Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.J Med Virol. 2013 Jul;85(7):1180-90. doi: 10.1002/jmv.23597. J Med Virol. 2013. PMID: 23918536
-
Resistance to direct antiviral agents in patients with hepatitis C virus infection.Gastroenterology. 2010 Feb;138(2):447-62. doi: 10.1053/j.gastro.2009.11.055. Epub 2009 Dec 16. Gastroenterology. 2010. PMID: 20006612 Review.
Cited by
-
Transcriptional Regulatory Networks in Hepatitis C Virus-induced Hepatocellular Carcinoma.Sci Rep. 2018 Sep 24;8(1):14234. doi: 10.1038/s41598-018-32464-5. Sci Rep. 2018. PMID: 30250040 Free PMC article.
-
Coronavirus Infection and Cholesterol Metabolism.Front Immunol. 2022 Apr 21;13:791267. doi: 10.3389/fimmu.2022.791267. eCollection 2022. Front Immunol. 2022. PMID: 35529872 Free PMC article. Review.
-
Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis.Sci Rep. 2021 Jul 6;11(1):13944. doi: 10.1038/s41598-021-93251-3. Sci Rep. 2021. PMID: 34230541 Free PMC article.
-
Molecular Events Occurring in Lipophagy and Its Regulation in Flaviviridae Infection.Front Microbiol. 2021 May 21;12:651952. doi: 10.3389/fmicb.2021.651952. eCollection 2021. Front Microbiol. 2021. PMID: 34093468 Free PMC article. Review.
-
Phospholipid profiles and hepatocellular carcinoma risk and prognosis in cirrhotic patients.Oncotarget. 2019 Mar 15;10(22):2161-2172. doi: 10.18632/oncotarget.26738. eCollection 2019 Mar 15. Oncotarget. 2019. PMID: 31040908 Free PMC article.
References
-
- Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17:107–115. - PubMed
-
- Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–1603. - PubMed
-
- Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–1888. - PubMed
-
- Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo P, Foster GR, Sulkowski MS, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370:222–232. - PubMed
-
- Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–1982. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical